Xiromed Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xiromed Llc Pharmaceutical Import Records from India — 2 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xiromed Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.2M Trade | TransData Nexus

Xiromed Llc

Pharmaceutical Importer · United States · Oncology Focus · $1.2M Total Trade · DGFT Verified

Xiromed Llc is a pharmaceutical importer based in United States with a total trade value of $1.2M across 2 products in 1 therapeutic categories. Based on 28 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xiromed Llc sources from 3 verified Indian suppliers, with Gland Pharma Limited accounting for 83.6% of imports.

Xiromed Llc — Import Portfolio & Supplier Network

Xiromed Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xiromed Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$1.0M	28	83.6%
Chemo India Formulation Private Limited	$104.5K	7	8.4%
Global Pharmatech Private Limited	$100.0K

What Formulations Does Xiromed Llc Import?

Formulation	Value	Ships
Fluorouracil	$782.1K	22
Irinotecan 20MG/5ML	$100.0K	2
Irinotecan hcl	$94.0K	2
Guanfacine tablets USP 2MG (5000's bulkpack)	$53.3K	3
Ephedrine sulfate injection USP 50MG/ml25 vials per cartonpacks 25sbatch no:e020a005 manufacturing	$50.0K	1
Ephedrine sulfate injection USP 50MG/ml25 vials per cartonpacks 25sbatch no:e020a004 manufacturing	$50.0K	1
Fluorouracil injection 1g/20ML 50MG/ML	$50.0K	1
Guanfacine tablets USP 1MG (5000's bulkpack)	$34.9K	3
Fluorouracil injection 2.5g/50ML	$20.1K	1
Ramelteon tablets 8 MG batch no. - 250041a (tablets=nos)	$16.3K	1

Xiromed Llc imports 10 distinct pharmaceutical formulations. Showing top 10 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluorouracil	Oncology	$999.8K	24	8.1%	3
2	Irinotecan	Oncology	$200.0K	4	0.5%	19

Xiromed Llc imports 2 pharmaceutical products across 1 categories into United States totaling $1.2M.

Xiromed Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xiromed LLC is a New Jersey-based generic pharmaceutical company specializing in the development, commercialization, and distribution of high-quality generic medications within the United States. Established in 2016, Xiromed operates as the U.S. generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. The company is committed to providing affordable and accessible generic drugs across various therapeutic areas, including oncology, dermatology, and women's health. Xiromed's portfolio encompasses a range of dosage forms, such as tablets, capsules, injectables, and inhalation products. The company's mission is to enhance patient access to essential medications while maintaining stringent quality standards.

2Distribution Network

Xiromed LLC's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. The company maintains a centralized warehouse located in Florham Park, New Jersey, serving as the primary hub for its operations. From this facility, Xiromed coordinates logistics to various regions, ensuring timely and reliable distribution to healthcare providers, pharmacies, and hospitals nationwide. While specific details about additional warehouse locations or international distribution are not publicly disclosed, Xiromed's partnership with Insud Pharma, S.L. suggests potential access to a broader global supply chain, enhancing its logistical capabilities.

3Industry Role

In the U.S. pharmaceutical supply chain, Xiromed LLC functions primarily as a generic pharmaceutical company, focusing on the development, marketing, and distribution of generic medications. The company does not operate as a wholesaler, parallel importer, hospital supplier, or logistics intermediary. Instead, Xiromed collaborates with various manufacturers, including those based in India, to source finished pharmaceutical formulations. These collaborations enable Xiromed to offer a diverse portfolio of generic drugs, thereby contributing to the availability of cost-effective treatment options within the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xiromed Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xiromed LLC's sourcing strategy exhibits a notable concentration on a limited number of suppliers, particularly from India. The company's import data indicates a total import value of $1.2 million USD from India, encompassing 28 shipments and 10 unique formulations across a single therapeutic category—oncology. The top two imported products are Fluorouracil, valued at $1 million USD (8.1% share), and Irinotecan, valued at $200,000 USD (0.5% share). This concentration suggests a strategic focus on oncology treatments sourced from Indian manufacturers. However, the heavy reliance on a few suppliers may pose risks related to supply chain disruptions, regulatory changes, or quality control issues. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Xiromed LLC's supply chain resilience is influenced by its sourcing practices, particularly the concentration on a limited number of suppliers from India. The company's import data reveals that three Indian suppliers—Gland Pharma Limited, Chemo India Formulation Private Limited, and Global Pharmatech Private Limited—account for the majority of its imports. This concentrated supplier base may expose Xiromed to potential risks, such as supply disruptions due to geopolitical factors, regulatory changes, or manufacturing issues. To enhance resilience, Xiromed could consider diversifying its supplier network and establishing relationships with additional manufacturers to ensure a more robust and flexible supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the approval, importation, and marketing of pharmaceutical products. The FDA ensures that all drugs, including generics, meet stringent standards for safety, efficacy, and quality before they can be marketed to the public. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval and importation. For Indian generics to be marketed in the U.S., they must receive approval through the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This regulatory framework ensures that imported generics maintain the same therapeutic effect as their brand-name counterparts.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Manufacturers and importers must register with the FDA and comply with Current Good Manufacturing Practice (CGMP) regulations to ensure product quality and safety. The FDA recognizes various international standards for CGMP compliance, including those from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). For Indian exporters, obtaining certifications from these recognized bodies can facilitate the acceptance of their products in the U.S. market. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S., ensuring that all intermediaries adhere to regulatory standards.

Xiromed Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xiromed LLC's focus on importing oncology products, particularly Fluorouracil and Irinotecan, aligns with the significant market demand for cancer treatments in the United States. The company's import data indicates a total import value of $1.2 million USD from India, with oncology products comprising the entire portfolio. This strategic emphasis allows Xiromed to address critical therapeutic needs while leveraging cost-effective sourcing from Indian manufacturers. The choice of these specific therapeutic areas is driven by the high prevalence of cancer and the ongoing need for affordable treatment options in the U.S. market.

2Sourcing Profile

Xiromed LLC's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from Indian manufacturers, focusing on oncology products. The company's import data reveals a total import value of $1.2 million USD from India, encompassing 28 shipments and 10 unique formulations across a single therapeutic category—oncology. This approach allows Xiromed to offer a specialized portfolio of generic oncology drugs, catering to the substantial demand for cancer treatments in the U.S. market. By sourcing from India, Xiromed benefits from cost-effective manufacturing while ensuring product quality through adherence to international standards.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xiromed Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Xiromed LLC, given the company's focus on importing oncology products. Indian exporters can explore partnerships by offering high-quality generic formulations that meet FDA standards and align with Xiromed's therapeutic focus. Gaps in Xiromed's current sourcing may include additional oncology drugs or other therapeutic areas where there is unmet demand in the U.S. market. By addressing these gaps, Indian suppliers can position themselves as valuable partners to Xiromed, contributing to the expansion of its

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Xiromed Llc

What products does Xiromed Llc import from India?

Xiromed Llc imports 2 pharmaceutical products across 1 categories. Top imports: Fluorouracil ($999.8K), Irinotecan ($200.0K).

Who supplies pharmaceuticals to Xiromed Llc from India?

Xiromed Llc sources from 3 verified Indian suppliers. The primary supplier is Gland Pharma Limited (83.6% of imports, $1.0M).

What is Xiromed Llc's total pharmaceutical import value?

Xiromed Llc's total pharmaceutical import value from India is $1.2M, based on 28 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xiromed Llc focus on?

Xiromed Llc imports across 1 categories. The largest: Oncology (100.0%).

Get Full Xiromed Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.